Vida and CDRD collaborate on drug development

Privately held Vida Therapeutics Inc is collaborating with the Centre for Drug Research and Development (CDRD) to advance its lead drug candidate to the commercial stage and position the firm for further private sector investment. CDRD synthesized and supplied the GzmB inhibitor drug compound to be used as a target for Vida's therapeutic strategy. The Vancouver-based firm is developing VTI-2002 — a highly specific and potent inhibitor of the GzmB enzyme found in elevated levels in patients with autoimmune and chronic inflammatory diseases such as lupus, Crohn's disease and multiple sclerosis....